[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GT201700138A - Pirazolpiridinaminas - Google Patents

Pirazolpiridinaminas

Info

Publication number
GT201700138A
GT201700138A GT201700138A GT201700138A GT201700138A GT 201700138 A GT201700138 A GT 201700138A GT 201700138 A GT201700138 A GT 201700138A GT 201700138 A GT201700138 A GT 201700138A GT 201700138 A GT201700138 A GT 201700138A
Authority
GT
Guatemala
Prior art keywords
compounds
labor
labor labor
prepare
pirazolpiridinaminas
Prior art date
Application number
GT201700138A
Other languages
English (en)
Inventor
Anja Giese Dra
Ulrich Klar Dr
Keith Graham Dr
Georg Kettschau Dr
Detlev Sülzle Dr
Philip Lienau Dr
Kirstinpetersen Dra
Julien Lefranc Dr
Nicole Schmidt Dra
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of GT201700138A publication Critical patent/GT201700138A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPUESTOS DE PIRAZOLPIRIDINAMINA SUSTITUIDA, MÉTODOS PARA PREPARAR DICHOS COMPUESTOS, COMPUESTOS INTERMEDIARIOS ÚTILES PARA PREPARAR DICHOS COMPUESTOS, COMPUESTOS, COMPOSICIONES FARMACÉUTICAS Y COMBINACIONES QUE COMPRENDEN A DICHOS COMPUESTOS Y EL USO DE DICHOS COMPUESTOS PARA ELABORAR UNA COMPOSICIÓN FARMACÉUTICA PARA EL TRATAMIENTO O LA PROFILAXIS DE UNA ENFERMEDAD, EN PARTICULAR DE UN TRASTORNO HIPERPROLIFERATIVO Y/O DE ANGIOGÉNESIS, ENFERMEDAD INFLAMATORIA Y ENFERMEDAD ASOCIADA CON DOLOR INFLAMATORIO, COMO ÚNICO AGENTE O EN COMBINACIÓN CON OTROS INGREDIENTES ACTIVOS.
GT201700138A 2014-12-19 2017-06-19 Pirazolpiridinaminas GT201700138A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14199096 2014-12-19
EP15187501 2015-09-29

Publications (1)

Publication Number Publication Date
GT201700138A true GT201700138A (es) 2018-12-06

Family

ID=54884024

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201700138A GT201700138A (es) 2014-12-19 2017-06-19 Pirazolpiridinaminas

Country Status (27)

Country Link
US (1) US10487092B2 (es)
EP (1) EP3233866B1 (es)
JP (1) JP2018501250A (es)
KR (1) KR20170095985A (es)
CN (1) CN107250138A (es)
AU (1) AU2015366417A1 (es)
BR (1) BR112017013148A2 (es)
CA (1) CA2971242A1 (es)
CL (1) CL2017001615A1 (es)
CO (1) CO2017005968A2 (es)
CR (1) CR20170264A (es)
CU (1) CU20170086A7 (es)
DO (1) DOP2017000146A (es)
EA (1) EA201791363A1 (es)
EC (1) ECSP17038893A (es)
GT (1) GT201700138A (es)
IL (1) IL252686A0 (es)
MX (1) MX2017008161A (es)
NI (1) NI201700078A (es)
PE (1) PE20171104A1 (es)
PH (1) PH12017501133A1 (es)
SG (1) SG11201704916TA (es)
SV (1) SV2017005466A (es)
TN (1) TN2017000258A1 (es)
TW (1) TW201625648A (es)
UY (1) UY36460A (es)
WO (1) WO2016096721A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
WO2017081003A1 (en) * 2015-11-12 2017-05-18 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyridinamines
CA3053493A1 (en) 2017-02-14 2018-08-23 Effector Therapeutics, Inc. Piperidine-substituted mnk inhibitors and methods related thereto
MX2021004763A (es) 2018-10-24 2021-06-08 Effector Therapeutics Inc Formas cristalinas de inhibidores de quinasa de interaccion con map quinasa (mnk).
CN111803476A (zh) * 2020-08-14 2020-10-23 华中科技大学协和深圳医院 芬戈莫德用于抑制革兰阳性细菌活性的用途
EP4211171A2 (en) 2020-09-10 2023-07-19 Precirix N.V. Antibody fragment against fap
US20230000986A1 (en) * 2021-07-01 2023-01-05 Board Of Regents, The University Of Texas System Mnk inhibitors and eif4e phosphorylation modulation to treat inflammatory pain in the aged
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
EP1651652B1 (en) * 2003-07-24 2006-12-27 Bayer Pharmaceuticals Corporation Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
US8207172B2 (en) * 2004-08-20 2012-06-26 Bayer Intellectual Property Gmbh Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders
US8703941B2 (en) 2011-01-10 2014-04-22 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
CN104507950B (zh) * 2012-05-21 2017-03-22 拜耳医药股份有限公司 噻吩并嘧啶
ES2592404T3 (es) 2012-05-21 2016-11-30 Bayer Pharma Aktiengesellschaft Benzotienopirimidinas sustituidas
US9546153B2 (en) * 2012-11-08 2017-01-17 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
US20160159816A1 (en) * 2013-02-01 2016-06-09 Bayer Pharma Aktiengesellschaft Substituted thienopyrimidines and pharmaceutical use thereof

Also Published As

Publication number Publication date
CA2971242A1 (en) 2016-06-23
MX2017008161A (es) 2017-09-18
JP2018501250A (ja) 2018-01-18
CR20170264A (es) 2017-07-21
DOP2017000146A (es) 2017-07-31
UY36460A (es) 2016-07-29
SG11201704916TA (en) 2017-07-28
US20180162877A1 (en) 2018-06-14
ECSP17038893A (es) 2017-07-31
PE20171104A1 (es) 2017-08-07
BR112017013148A2 (pt) 2019-11-19
CN107250138A (zh) 2017-10-13
EP3233866A1 (en) 2017-10-25
CU20170086A7 (es) 2017-11-07
PH12017501133A1 (en) 2017-11-27
IL252686A0 (en) 2017-08-31
TW201625648A (zh) 2016-07-16
US10487092B2 (en) 2019-11-26
CO2017005968A2 (es) 2017-10-20
SV2017005466A (es) 2018-10-02
EP3233866B1 (en) 2021-04-21
TN2017000258A1 (en) 2018-10-19
KR20170095985A (ko) 2017-08-23
CL2017001615A1 (es) 2018-03-16
EA201791363A1 (ru) 2018-01-31
NI201700078A (es) 2017-09-22
WO2016096721A1 (en) 2016-06-23
AU2015366417A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
GT201700138A (es) Pirazolpiridinaminas
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
ECSP17007538A (es) 2-(morfolin-4-il)-1,7-naftiridinas
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
NI201500118A (es) Imidazopiridazinas sustituidas
CO2017001994A2 (es) Compuestos activos hacia bromodominios
DOP2016000007A (es) Pirazolpiridinas sustituidas
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
CR20160433A (es) Nuevos compuestos
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CO2018008626A2 (es) Formulaciones de oritavancina
UY36983A (es) Pirazolopiridinaminas sustituidas
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
CL2015003211A1 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
UY37012A (es) Formulaciones de giberelina
AR100593A1 (es) Composición sinérgica surfactante
AR099681A1 (es) Composiciones de grapiprant y métodos para su utilización